Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis.
Anemia
/ blood
Arthralgia
/ physiopathology
Arthritis, Juvenile
/ blood
Child
Child, Preschool
Exanthema
/ physiopathology
Female
Fever
/ physiopathology
Hepatomegaly
/ physiopathology
Humans
Hyperferritinemia
/ blood
Lymphadenopathy
/ physiopathology
Male
Pain Measurement
Quality of Life
Range of Motion, Articular
Reproducibility of Results
Serositis
/ physiopathology
Severity of Illness Index
Splenomegaly
/ physiopathology
Thrombocytosis
/ blood
Still’s disease
clinical assessment
composite disease activity score
disease activity
outcome measures
pediatric rheumatology
systemic juvenile idiopathic arthritis
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
01 Nov 2020
01 Nov 2020
Historique:
received:
31
12
2019
revised:
06
04
2020
pubmed:
24
8
2020
medline:
2
2
2021
entrez:
24
8
2020
Statut:
ppublish
Résumé
To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 weeks to 3 months after baseline. Three versions were examined, including ESR, CRP or no acute-phase reactant. A total of 163 patients were included at 30 centres in 10 countries. The sJADAS was found to be feasible and to possess face and content validity, good construct validity, satisfactory internal consistency (Cronbach's alpha 0.64-0.65), fair ability to discriminate between patients with different disease activity states and between those whose parents were satisfied or not satisfied with illness outcome (P < 0.0001 for both), and strong responsiveness to change over time (standardized response mean 2.04-2.58). Overall, these properties were found to be better than those of the original JADAS and of DAS for RA and of Puchot score for adult-onset Still's disease. The sJADAS showed good measurement properties and is therefore a valid instrument for the assessment of disease activity in children with sJIA. The performance of the new tool should be further examined in other patient cohorts that are evaluated prospectively.
Identifiants
pubmed: 32829413
pii: 5896157
doi: 10.1093/rheumatology/keaa240
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3505-3514Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.